MC2R and adrenal cortex carcinoma: A phase I trial of 68Ga-R8760, a radiopharmaceutical targeting the melanocortin 2 receptor (MC2R), for imaging of metastatic ACC is currently enrolling.100 To our knowledge, a counterpart therapeutic radiopharmaceutical targeting MC2R has not yet been developed.